ArticleDiscover oncology2025
Identification and validation of the fibrosis-related molecular subtypes of hepatocellular carcinoma by bioinformatics.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We identified novel Molecular subtypes according to the expression of fibrosis-related genes (FRGs) and constructed a prognostic model using different expression genes (DEGs) for patients with Hepatocellular carcinoma (HCC). We downloaded the clinical data and transcriptome data of HCC from The Cancer Genome Atlas (TCGA) database, Gene Expression Omnibus (GEO) database, and International Cancer Genome Consortium (ICGC) database. We identified two fibrosis-related molecular subtypes of HCC by consensus unsupervised clustering analysis. Interestingly, these two molecular subtypes significantly differed in overall survival (OS) and clinical characteristics. Besides, the most minor absolute shrinkage and selection operator (Lasso) and multivariate Cox regression analysis were performed to develop a novel prognostic model by three genes (including KPNA2, LPCAT1, and AKR1D1). There was a statistically significant difference in OS between the high-risk and low-risk groups. The area under the ROC curve (AUC) of OS in 1-, 3-, and 5-year were satisfactory. Besides, the risk score was connected with critical clinical characteristics and could be an independent factor in predicting prognosis. Then, the nomogram was built by incorporating risk scores with clinical parameters. Additionally, the risk score was remarkedly correlated with TME and drug susceptibility. Finally, the results of H&E staining and immunohistochemistry of Ki67 showed that the tumor of higher-risk patients are more malignant. The FRGs-based subtype and signature explain the HCC heterogeneity, which might provide a new method to develop a more efficient treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.